Back to top

Image: Bigstock

Valeant Pharmaceuticals International, Inc.

Read MoreHide Full Article

Valeant’s third-quarter results were strong with the company beating on both the top and bottom lines. However, it recently cut its guidance for the fourth quarter 2015 and the full year. It also ended its relationship with Philidor, thereby losing 20% prescriptions and $250 million in sales in the fourth quarter. Valeant has been making headlines since Aug 2015 for reasons like price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services. Its dermatology business was also impacted. To make amends, the company entered into an agreement with Walgreens Boot Alliance to lower prices of all dermatological and ophthalmological products by 10% that are distributed through Walgreens’ outlets.